Celivir: A Viral Therapy for the Autoimmune Celiac Disease

Jose Crespo-Barrios^1,

¹Free of Affiliation

Cite this paper:
Jose Crespo-Barrios. Celivir: A Viral Therapy for the Autoimmune Celiac Disease. International Journal of Celiac Disease. 2023; 11(1):36-37. doi: 10.12691/ijcd-11-1-8

Abstract

With an average of 1/200 affected people around the world, celiac disease still lacks a cure. Here a concept of a viral therapy with certain design degrees of freedom is suggested to the scientific community with the hope that a well experienced and equipped research team is able to endeavour such project. Also, safety concerns of the viral therapy about escape mutations and trophism are covered. These ideas can be extended to any autoimmune disease with an etiological alteration of the memory T-cells, paving the way to safer alternatives to the immunological reboot.

Keywords:
celiac autoimmunity viral therapy escape mutation

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Patterson BK, Francisco EB, Mora J, et al.; CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection; Front. Immunol. 10; 2022.
[2]	Shen, XR., Geng, R., Li, Q. et al. ACE2-independent infection of T lymphocytes by SARS-CoV-2. Sig Transduct Target Ther 7, 83; 2022.
[3]	Huang, Y., Yang, C., Xu, Xf. et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin 41, 1141-1149; 2020.
[4]	Stem Cells to Treat Crohn’s Disease; 2009; https:/ crohns-disease.